Psyence Group Sells Stake to Psyence Biomedical
Company Announcements

Psyence Group Sells Stake to Psyence Biomedical

Story Highlights

Psyence Group (TSE:PSYG) has released an update.

Psyence Group has successfully closed the disposal of its 11.13% stake in PsyLabs to Psyence Biomedical, receiving 2,000,000 shares of Psyence Biomedical’s common stock as part of the transaction. This strategic move strengthens Psyence Biomedical’s position as a vertically integrated developer of psychedelic-based therapeutics. Additionally, a debt-for-equity swap agreement was executed, further aligning the financial interests of both companies.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Expands Psilocybin Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPsyence Group Enhances Liquidity with Equity Swap
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App